No Data
Express News | Cogent Biosciences Inc : Guggenheim Cuts Target Price to $17 From $20
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $21
Cogent Biosciences Is Maintained at Buy by Needham
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $15
Express News | Cogent Biosciences Inc : Needham Cuts Target Price to $15 From $16
Cogent Biosciences: Buy Rating Affirmed Amid Anticipation for Bezuclastinib Data and Strong Financial Position